Guillermo Federico Bramuglia
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Guillermo Federico Bramuglia has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Bosaleh
Pathology Service, J.P. Garrahan Hospital, Buenos Aires C1245AAM, Argentina
1 shared publication Damián Consalvo
1 shared publication- Esteban Halac
Liver Transplant Service, J.P. Garrahan Hospital, Buenos Aires C1245AAM, Argentina
1 shared publication - Florencia Fernandez
Instituto de Investigaciones Farmacológicas, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Ciudad Autónoma de Buenos Aires C1113AAA, Argentina
1 shared publication - Jefferson Antonio Buendía
Departamento de Farmacología y Toxicología, Facultad de Medicina, Grupo de Investigación en Farmacología y Toxicología, Universidad de Antioquia, Medellín, Colombia
1 shared publication - Mariano Núñez1 shared publication
Latest Publications
- Open Access
- 26 September 2023
- Published by AccScience Publishing in Global Translational Medicine
- Vol. 2 (3) , 1265
A simple, fast, and cost-effective high-performance liquid chromatography-ultraviolet validated method to quantify lacosamide in therapeutic drug monitoring
AccScience Publishing is a publishing company based in Singapore. We have in our portfolio a range of high-quality, open-access, peer-reviewed journals and books from a broad spectrum of science, technology, biomedicine, engineering, education, social sciences and many more.
- 26 September 2023
- Published by AccScience Publishing in Global Translational Medicine
- Vol. 2 (3) , 1265
Open AccessA simple, fast, and cost-effective high-performance liquid chromatography-ultraviolet validated method to quantify lacosamide in therapeutic drug monitoring
AccScience Publishing is a publishing company based in Singapore. We have in our portfolio a range of high-quality, open-access, peer-reviewed journals and books from a broad spectrum of science, technology, biomedicine, engineering, education, social sciences and many more.
- Open Access
- 22 September 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (9) , 898
Frequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
The evidence available in the pediatric population is limited for making clinical decisions regarding the optimization of tacrolimus (TAC) in pharmacotherapy. The objective of this study was to estimate the frequency of CYP3A5 genetic polymorphisms and their relationship with tacrolimus requirements in the pediatric population. This was a longitudinal cohort study with a two-year follow-up of 77 patients under 18 years old who underwent a liver transplant during the period 2009–2012 at the J.P. Garrahan Pediatric Hospital. Tacrolimus levels from day five up to two years after the transplant were obtained from hospital records of routine therapeutic drug monitoring. The genotyping of CYP3A5 (CYP3A5*1/*3 or *3/*3) was performed in liver biopsies from both the donor and the recipient. The frequency of CYP3A5*1 expression for recipients was 37.1% and 32.2% for donors. Patients who received an expresser organ showed lower Co/dose, especially following 90 days after the surgery. The role of each polymorphism is different according to the number of days after the transplant, and it must be taken into account to optimize the benefits of TAC therapy during the post-transplant induction and maintenance phases.
- 22 September 2020
- Published by MDPI AG in Pharmaceutics
- Vol. 12 (9) , 898
Open AccessFrequency of CYP3A5 Genetic Polymorphisms and Tacrolimus Pharmacokinetics in Pediatric Liver Transplantation
The evidence available in the pediatric population is limited for making clinical decisions regarding the optimization of tacrolimus (TAC) in pharmacotherapy. The objective of this study was to estimate the frequency of CYP3A5 genetic polymorphisms and their relationship with tacrolimus requirements in the pediatric population. This was a longitudinal cohort study with a two-year follow-up of 77 patients under 18 years old who underwent a liver transplant during the period 2009–2012 at the J.P. Garrahan Pediatric Hospital. Tacrolimus levels from day five up to two years after the transplant were obtained from hospital records of routine therapeutic drug monitoring. The genotyping of CYP3A5 (CYP3A5*1/*3 or *3/*3) was performed in liver biopsies from both the donor and the recipient. The frequency of CYP3A5*1 expression for recipients was 37.1% and 32.2% for donors. Patients who received an expresser organ showed lower Co/dose, especially following 90 days after the surgery. The role of each polymorphism is different according to the number of days after the transplant, and it must be taken into account to optimize the benefits of TAC therapy during the post-transplant induction and maintenance phases.